Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Pharmacotherapeutic considerations in women with multiple sclerosis

Research output: Contribution to journalReviewResearchpeer-review

  1. Pharmacological strategies to treat attacks of episodic migraine in adults

    Research output: Contribution to journalReviewResearchpeer-review

  2. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  3. Treatment of adult short bowel syndrome patients with teduglutide

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Irinotecan and bevacizumab in recurrent glioblastoma multiforme

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Therapeutic management of type 1 diabetes before and during pregnancy

    Research output: Contribution to journalJournal articleResearch

  1. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Danish Multiple Sclerosis Registry

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Multiple sclerosis (MS) is a chronically progressive disease of the central nervous system. The relapsing form of the disease predominantly affects women with onset between the ages 20 to 40 years. Therefore, timing, choice, and treatment options should take pregnancy planning into consideration to accommodate both the needs and safety of the mother and health of the fetus.

AREAS COVERED: In this review, the authors discuss and summarize the recent evidence of different pharmacotherapeutic possibilities in the treatment of women with MS.

EXPERT OPINION: There is evidence that disease modifying therapy reduces the risk of relapses and diminishes disability progression in people with relapsing MS. The disease is often diagnosed in the childbearing years, and thus pregnancy planning can possibly be a part of the pharmacotherapeutic considerations. The management of women planning pregnancy requires a balancing of risks. The clinician must consider the risks related to treatment discontinuation versus the risk of exposing the developing fetus to drugs that are potential fetotoxic. Randomized controlled trials of medication safety - if used during pregnancy, are prohibited for ethical reasons; hence, the evidence is continuously gathered from observational data, post-authorization studies and pregnancy registries.

Original languageEnglish
JournalExpert Opinion on Pharmacotherapy
Volume21
Issue number13
Pages (from-to)1591-1602
Number of pages12
ISSN1465-6566
DOIs
Publication statusPublished - Sep 2020

    Research areas

  • Adult, Antibodies, Monoclonal/therapeutic use, Disease Progression, Female, Fertility/drug effects, Humans, Immunologic Factors/therapeutic use, Multiple Sclerosis, Relapsing-Remitting/drug therapy, Pregnancy, Pregnancy Complications/drug therapy, Pregnancy Outcome, Treatment Outcome, Young Adult, disease modifying therapy, multiple sclerosis, pregnancy, Pharmacotherapeutic considerations, women

ID: 61976062